Poly(o-toluidine) salt as low cost electrode material for high performance electrochemical supercapacitor

Binder-free, low cost poly(o-toluidine) (POT) has been synthesized by emulsion polymerization method. The synthesized POT salt has been tested for supercapacitor application through cyclic voltammetry and galvanostatic charge discharge analysis. The POT salt exhibits a specific capacitance value of 301 F/g. The synthesized material was further characterized by FTIR, UV-visible spectroscopy and X-ray diffraction analysis

Study on Direct Synthesis of Energy Efficient Multifunctional Polyaniline-Graphene Oxide Nanocomposite and Its Application in Aqueous Symmetric Supercapacitor Devices

The synthesis of promising nanocomposite materials can always be tricky and depends a lot on the method of synthesis itself. Developing such synthesis routes, which are not only simple but also can effectively catch up the synergy of the compositing material, is definitely a worthy contribution towards nanomaterial science. Carbon-based materials, such as graphene oxide, and conjugative polymers, such as conductive polyaniline, are considered materials of the 21st century. This study involves a simple one pot synthesis route for obtaining a nanocomposite of polyaniline and graphene oxide with synergistic effects. The study was carried out in a systematic way by gradually changing the composition of the ingredients in the reaction bath until the formation of nanocomposite took place at some particular reaction parameters. These nanocomposites were then utilized for the fabrication of electrodes for aqueous symmetric supercapacitor devices utilizing gold or copper as current collectors. The device manifested a good capacitance value of 264 F/g at 1 A/g, magnificent rate performance, and capacitance retention of 84.09% at a high current density (10 A/g) when gold sheet electrodes were used as the current collectors. It also showed a capacitance retention of 79.83% and columbic efficiency of 99.83% after 2000 cycles

Diagnostic Accuracy Of Placental Thickness Measured By Ultrasonography In The Detection Of Intrauterine Growth Restricted (IUGR) Babies Keeping Actual Birth Weight As Gold Standard

Objective: To determine the diagnostic accuracy of the placental thickness measured by ultrasound in detecting IUGR babies keeping actual birth weight as the gold standard. Methods: This cross-sectional validation study was conducted in the Department of Radiology P.O.F Hospital Wah Cantt. The data was gathered over a period of six months, from 06-19-2017 to 12-18-2017. A total of 125 patients were included in this study. All pregnant women were examined by the greyscale and Doppler ultrasonography using a color Doppler scanner with a 5.0 MHz convex probe. Placental thickness was measured as the distance between the echogenic line of the chorionic plate and the hypoechoic myometrium. The pregnant females were followed till childbirth and the weight of the baby at birth was recorded. Results: Patients ranged between 20-35 years of age. The average age of the study participants was 27.6±3.3 years, the mean gestational age was 34.2±3.0 weeks, the mean BMI was 23.5±1.3 (kg/m2), and the mean parity was 1.1±1.0. We found a sensitivity of 65.5%, specificity of 83.3%, Positive Predictive Value( PPV) of 98.7%, Negative Predictive Value (NPV) of 10.8%, and diagnostic accuracy of 66.4% for antenatal prediction of IUGR based on placental thickness measurement. Stratification for age and gestational age was also carried out. Conclusion: Placental thickness on ultrasonography can be used as a reliable marker for detecting IUGR babies with an accuracy of 6.4%

Investigation of Alumina-Doped Prunus domestica Gum Grafted Polyaniline Epoxy Resin for Corrosion Protection Coatings for Mild Steel and Stainless Steel

Eco-friendly inhibitors have attracted considerable interest due to the increasing environmental issues caused by the extensive use of hazardous corrosion inhibitors. In this paper, environmentally friendly PDG-g-PANI/Al$_2$O$_3$ composites were prepared by a low-cost inverse emulsion polymerization for corrosion inhibition of mild steel (MS) and stainless steel (SS). The PDG-g-PANI/Al$_2$O$_3$ composites were characterized by different techniques such as X-ray diffraction (XRD), UV/Vis, and FTIR spectroscopy. XRD measurements show that the PDG-g-PANI/Al$_2$O$_3$ composite is mostly amorphous and scanning electron micrographs (SEM) reveal a uniform distribution of Al$_2$O$_3$ on the surface of the PDG-g-PANI matrix. The composite was applied as a corrosion inhibitor on mild steel (MS) and stainless steel (SS), and its efficiency was investigated by potentiodynamic polarization measurement in a 3.5% NaCl and 1 M H$_2$SO$_4$ solution. Corrosion kinetic parameters obtained from Tafel evaluation show that the PDG-g-PANI/Al$_2$O$_3$ composites protect the surface of MS and SS with inhibition efficiencies of 92.3% and 51.9% in 3.5% NaCl solution, which is notably higher than those obtained with untreated epoxy resin (89.3% and 99.5%). In particular, the mixture of epoxy/PDG-g-PANI/Al$_2$O$_3$ shows the best performance with an inhibition efficiency up to 99.9% on MS and SS. An equivalent good inhibition efficiency was obtained for the composite for 1M H$_2$SO$_4$. Analysis of activation energy, formation enthalpy, and entropy values suggest that the epoxy/PDG-g-PANI/Al$_2$O$_3$ coating is thermodynamically favorable for corrosion protection of MS and exhibits long-lasting stability

Achieving Ultrahigh Cycling Stability and Extended Potential Window for Supercapacitors through Asymmetric Combination of Conductive Polymer Nanocomposite and Activated Carbon

Conducting polymers and carbon-based materials such as graphene oxide (GO) and activated carbon (AC) are the most promising capacitive materials, though both offer charge storage through different mechanisms. However, their combination can lead to some unusual results, offering improvement in certain properties in comparison with the individual materials. Cycling stability of supercapacitors devices is often a matter of concern, and extensive research is underway to improve this phenomena of supercapacitive devices. Herein, a high-performance asymmetric supercapacitor device was fabricated using graphene oxide–polyaniline (GO@PANI) nanocomposite as positive electrode and activated carbon (AC) as negative electrode. The device showed 142 F g−1 specific capacitance at 1 A g−1 current density with capacitance retention of 73.94% at higher current density (10 A g−1). Most importantly, the device exhibited very high electrochemical cycling stability. It retained 118.6% specific capacitance of the starting value after 10,000 cycles at 3 Ag−1 and with coulombic efficiency of 98.06 %, indicating great potential for practical applications. Very small solution resistance (Rs, 0.640 Ω) and charge transfer resistance (Rct, 0.200 Ω) were observed hinting efficient charge transfer and fast ion diffusion. Due to asymmetric combination, potential window was extended to 1.2 V in aqueous electrolyte, as a result higher energy density (28.5 Wh kg−1) and power density of 2503 W kg−1 were achieved at the current density 1 Ag−1. It also showed an aerial capacitance of 57 mF cm−2 at current 3.2 mA cm−2. At this current density, its energy density was maximum (0.92 mWh cm−2) with power density (10.47 W cm−2)

Fabrication of Eco-Friendly Solid-State Symmetric Ultracapacitor Device Based on Co-Doped PANI/GO Composite

An eco-friendly solid-state symmetric ultracapacitor (Uc) device was fabricated using a polyaniline graphene oxide composite co-doped with sulfuric acid (H2SO4) and dodecyl benzene sulfonic acid (DBSA) or camphor sulfonic acid (CSA), as electrode material utilizing gold sheets as current collectors. The device showed specific capacitance value of 150 F/g at 1 A/g current density, with a capacitance retention value of 93.33% at higher current density (10 A/g), indicating a high rate capability. An energy density of 15.30 Whkg-1 with a power density of 1716 Wkg-1 was obtained at the current density of 1 A/g. The values of areal capacitance, power density, and energy density, achieved at the current density of 5 mAcm-2, were 97.38 mFcm-2, 9.93 mWhcm-2, and 1.1 Wcm-2, respectively. Additionally, the device showed very low solution and charge transfer resistance (0.885 Ω and 0.475 Ω, respectively). A device was also fabricated utilizing copper as current collector; however, a lower value of specific capacitance (82 F/g) was observed in this case

Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis

BACKGROUND: Rates of antimicrobial resistance (AMR) are rising globally and there is concern that increased migration is contributing to the burden of antibiotic resistance in Europe. However, the effect of migration on the burden of AMR in Europe has not yet been comprehensively examined. Therefore, we did a systematic review and meta-analysis to identify and synthesise data for AMR carriage or infection in migrants to Europe to examine differences in patterns of AMR across migrant groups and in different settings. METHODS: For this systematic review and meta-analysis, we searched MEDLINE, Embase, PubMed, and Scopus with no language restrictions from Jan 1, 2000, to Jan 18, 2017, for primary data from observational studies reporting antibacterial resistance in common bacterial pathogens among migrants to 21 European Union-15 and European Economic Area countries. To be eligible for inclusion, studies had to report data on carriage or infection with laboratory-confirmed antibiotic-resistant organisms in migrant populations. We extracted data from eligible studies and assessed quality using piloted, standardised forms. We did not examine drug resistance in tuberculosis and excluded articles solely reporting on this parameter. We also excluded articles in which migrant status was determined by ethnicity, country of birth of participants' parents, or was not defined, and articles in which data were not disaggregated by migrant status. Outcomes were carriage of or infection with antibiotic-resistant organisms. We used random-effects models to calculate the pooled prevalence of each outcome. The study protocol is registered with PROSPERO, number CRD42016043681. FINDINGS: We identified 2274 articles, of which 23 observational studies reporting on antibiotic resistance in 2319 migrants were included. The pooled prevalence of any AMR carriage or AMR infection in migrants was 25·4% (95% CI 19·1-31·8; I2 =98%), including meticillin-resistant Staphylococcus aureus (7·8%, 4·8-10·7; I2 =92%) and antibiotic-resistant Gram-negative bacteria (27·2%, 17·6-36·8; I2 =94%). The pooled prevalence of any AMR carriage or infection was higher in refugees and asylum seekers (33·0%, 18·3-47·6; I2 =98%) than in other migrant groups (6·6%, 1·8-11·3; I2 =92%). The pooled prevalence of antibiotic-resistant organisms was slightly higher in high-migrant community settings (33·1%, 11·1-55·1; I2 =96%) than in migrants in hospitals (24·3%, 16·1-32·6; I2 =98%). We did not find evidence of high rates of transmission of AMR from migrant to host populations. INTERPRETATION: Migrants are exposed to conditions favouring the emergence of drug resistance during transit and in host countries in Europe. Increased antibiotic resistance among refugees and asylum seekers and in high-migrant community settings (such as refugee camps and detention facilities) highlights the need for improved living conditions, access to health care, and initiatives to facilitate detection of and appropriate high-quality treatment for antibiotic-resistant infections during transit and in host countries. Protocols for the prevention and control of infection and for antibiotic surveillance need to be integrated in all aspects of health care, which should be accessible for all migrant groups, and should target determinants of AMR before, during, and after migration. FUNDING: UK National Institute for Health Research Imperial Biomedical Research Centre, Imperial College Healthcare Charity, the Wellcome Trust, and UK National Institute for Health Research Health Protection Research Unit in Healthcare-associated Infections and Antimictobial Resistance at Imperial College London

Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial

Background Post-partum haemorrhage is the leading cause of maternal death worldwide. Early administration of tranexamic acid reduces deaths due to bleeding in trauma patients. We aimed to assess the effects of early administration of tranexamic acid on death, hysterectomy, and other relevant outcomes in women with post-partum haemorrhage. Methods In this randomised, double-blind, placebo-controlled trial, we recruited women aged 16 years and older with a clinical diagnosis of post-partum haemorrhage after a vaginal birth or caesarean section from 193 hospitals in 21 countries. We randomly assigned women to receive either 1 g intravenous tranexamic acid or matching placebo in addition to usual care. If bleeding continued after 30 min, or stopped and restarted within 24 h of the first dose, a second dose of 1 g of tranexamic acid or placebo could be given. Patients were assigned by selection of a numbered treatment pack from a box containing eight numbered packs that were identical apart from the pack number. Participants, care givers, and those assessing outcomes were masked to allocation. We originally planned to enrol 15 000 women with a composite primary endpoint of death from all-causes or hysterectomy within 42 days of giving birth. However, during the trial it became apparent that the decision to conduct a hysterectomy was often made at the same time as randomisation. Although tranexamic acid could influence the risk of death in these cases, it could not affect the risk of hysterectomy. We therefore increased the sample size from 15 000 to 20 000 women in order to estimate the effect of tranexamic acid on the risk of death from post-partum haemorrhage. All analyses were done on an intention-to-treat basis. This trial is registered with ISRCTN76912190 (Dec 8, 2008); ClinicalTrials.gov, number NCT00872469; and PACTR201007000192283. Findings Between March, 2010, and April, 2016, 20 060 women were enrolled and randomly assigned to receive tranexamic acid (n=10 051) or placebo (n=10 009), of whom 10 036 and 9985, respectively, were included in the analysis. Death due to bleeding was significantly reduced in women given tranexamic acid (155 [1·5%] of 10 036 patients vs 191 [1·9%] of 9985 in the placebo group, risk ratio [RR] 0·81, 95% CI 0·65–1·00; p=0·045), especially in women given treatment within 3 h of giving birth (89 [1·2%] in the tranexamic acid group vs 127 [1·7%] in the placebo group, RR 0·69, 95% CI 0·52–0·91; p=0·008). All other causes of death did not differ significantly by group. Hysterectomy was not reduced with tranexamic acid (358 [3·6%] patients in the tranexamic acid group vs 351 [3·5%] in the placebo group, RR 1·02, 95% CI 0·88–1·07; p=0·84). The composite primary endpoint of death from all causes or hysterectomy was not reduced with tranexamic acid (534 [5·3%] deaths or hysterectomies in the tranexamic acid group vs 546 [5·5%] in the placebo group, RR 0·97, 95% CI 0·87-1·09; p=0·65). Adverse events (including thromboembolic events) did not differ significantly in the tranexamic acid versus placebo group. Interpretation Tranexamic acid reduces death due to bleeding in women with post-partum haemorrhage with no adverse effects. When used as a treatment for postpartum haemorrhage, tranexamic acid should be given as soon as possible after bleeding onset. Funding London School of Hygiene & Tropical Medicine, Pfizer, UK Department of Health, Wellcome Trust, and Bill & Melinda Gates Foundation

Surgical site infection after gastrointestinal surgery in high-income, middle-income, and low-income countries: a prospective, international, multicentre cohort study

Background: Surgical site infection (SSI) is one of the most common infections associated with health care, but its importance as a global health priority is not fully understood. We quantified the burden of SSI after gastrointestinal surgery in countries in all parts of the world. Methods: This international, prospective, multicentre cohort study included consecutive patients undergoing elective or emergency gastrointestinal resection within 2-week time periods at any health-care facility in any country. Countries with participating centres were stratified into high-income, middle-income, and low-income groups according to the UN's Human Development Index (HDI). Data variables from the GlobalSurg 1 study and other studies that have been found to affect the likelihood of SSI were entered into risk adjustment models. The primary outcome measure was the 30-day SSI incidence (defined by US Centers for Disease Control and Prevention criteria for superficial and deep incisional SSI). Relationships with explanatory variables were examined using Bayesian multilevel logistic regression models. This trial is registered with ClinicalTrials.gov, number NCT02662231. Findings: Between Jan 4, 2016, and July 31, 2016, 13 265 records were submitted for analysis. 12 539 patients from 343 hospitals in 66 countries were included. 7339 (58·5%) patient were from high-HDI countries (193 hospitals in 30 countries), 3918 (31·2%) patients were from middle-HDI countries (82 hospitals in 18 countries), and 1282 (10·2%) patients were from low-HDI countries (68 hospitals in 18 countries). In total, 1538 (12·3%) patients had SSI within 30 days of surgery. The incidence of SSI varied between countries with high (691 [9·4%] of 7339 patients), middle (549 [14·0%] of 3918 patients), and low (298 [23·2%] of 1282) HDI (p < 0·001). The highest SSI incidence in each HDI group was after dirty surgery (102 [17·8%] of 574 patients in high-HDI countries; 74 [31·4%] of 236 patients in middle-HDI countries; 72 [39·8%] of 181 patients in low-HDI countries). Following risk factor adjustment, patients in low-HDI countries were at greatest risk of SSI (adjusted odds ratio 1·60, 95% credible interval 1·05–2·37; p=0·030). 132 (21·6%) of 610 patients with an SSI and a microbiology culture result had an infection that was resistant to the prophylactic antibiotic used. Resistant infections were detected in 49 (16·6%) of 295 patients in high-HDI countries, in 37 (19·8%) of 187 patients in middle-HDI countries, and in 46 (35·9%) of 128 patients in low-HDI countries (p < 0·001). Interpretation: Countries with a low HDI carry a disproportionately greater burden of SSI than countries with a middle or high HDI and might have higher rates of antibiotic resistance. In view of WHO recommendations on SSI prevention that highlight the absence of high-quality interventional research, urgent, pragmatic, randomised trials based in LMICs are needed to assess measures aiming to reduce this preventable complication